The upcoming study will compare the effects of DMT and a placebo in stroke patients. The post Algernon sells Ifenprodil, zooms in on DMT for stroke...
The firm said it feels comfortable about its runway through 2026. The post Atai cash purse down nearly half despite lower spending appeared first on Green...
The firm is trying to advance its lead compound, REL-1017, through late-stage clinical trials. The post Relmada Therapeutics trims losses, slashes research...
Biotech company Seelos Therapeutics, Inc. (Nasdaq: SEEL) told investors on Tuesday that its drug SLS-005 (IV trehalose) failed a study to treat amyotrophic...
The drug aims to be effective like ibogaine but without the heart risks. The post Gilgamesh secures $14M for ibogaine-like drug appeared first on Green...
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue...
Toronto-based Cybin Inc. (NYSE:CYBN) will be raising roughly $150 million through the private placement of more than 348 million common shares to continue...
The new Nasdaq-listed entity trades under the ticker symbol PBM. The post Australia approves Psyence phase 2b study as it finalizes merger appeared first...
The JAMA (Journal of American Medical Association) Psychiatry published an article calling for more research and surveillance of ketamine treatments. Citing...
The company is still reeling with negative cash flows and net losses. The post Mynd Life Sciences cuts losses, but faces going concern doubts appeared...